Neogen Corporation (NASDAQ: NEOG), headquartered in Lansing, Michigan, is scheduled to report its first-quarter financial results before the market opens on Thursday, January 8, 2025. Market analysts project that the company will report earnings per share (EPS) of 7 cents, marking a decrease from 11 cents per share during the same quarter last year.
In terms of revenue, the consensus across analysts anticipates Neogen generating approximately $208.38 million in quarterly sales, which represents a decline compared to the $231.26 million reported in the year-ago period. These figures reflect expectations of contraction in both profitability and revenue streams for the company amid current market dynamics.
In early January, Neogen made significant leadership appointments to potentially steer its growth initiatives. The company named Joe Freels as Senior Vice President and Chief Commercial Officer. Concurrently, Dr. Tammi Ranalli was appointed Senior Vice President and General Manager of Global Food Safety, indicating a focus on strengthening the commercial operations and food safety divisions.
Neogen’s stock performance has shown resilience in the lead-up to the earnings announcement, with shares inching upward by 2.1%, closing at $7.41 on the Tuesday preceding the report release. This market movement reflects cautious optimism despite the mixed financial outlook.
Wall Street's most accurate analysts have recently updated their recommendations and price targets for NEOG, offering a spectrum of perspectives on the stock’s potential trajectory.
- On December 10, 2025, Robert Labick of CJS Securities upgraded Neogen's rating from Market Perform to Market Outperform, setting a price target of $10 per share. Labick possesses an accuracy rate of 53%, lending moderate confidence to his upgrade.
- David Westenberg from Piper Sandler upheld a Neutral rating on October 16, 2025, while adjusting his price target upward from $5 to $6.50. With a 76% accuracy record, Westenberg’s assessment suggests cautious steadiness with a modest valuation bump.
- Brandon Vazquez at William Blair revised his stance on July 29, 2025, downgrading Neogen from Outperform to Market Perform. Vazquez’s 68% accuracy provides solid, though not definitive, backing for this more conservative outlook.
- Subbu Nambi, an analyst with Guggenheim, maintained a Buy rating as of June 30, 2025, but lowered the price target from $13 to $10. Nambi's 65% accuracy rate highlights a tempered yet positive view of Neogen's prospects.
These diverse analyst opinions reflect the market’s nuanced expectations ahead of the earnings release, balancing Neogen’s recent strategic leadership changes against its projected financial challenges.
For investors considering NEOG stock, the evolving ratings and price targets emphasize the importance of monitoring forthcoming earnings announcements and subsequent market reactions to assess Neogen’s operational and financial momentum.